Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Nektar buys out Aerogen for $32 m



17th August,2005: Nektar Therapeutics is tipped to acquire Aerogen in a transaction valued at approximately $32 million. Nektar has signed a definitive agreement with Aerogen finalizing the transaction, the company said in a press release.

The acquisition of Aerogen broadens Nektar's pulmonary delivery capabilities by adding advanced inhaleable liquid drug technology to Nektar's base of leading inhaleable powdered drug technology, the Nektar release noted. 

Aerogen develops products based on its OnQ Aerosol Generator technology for the treatment of respiratory disorders in the acute care setting. Nektar enables differentiated therapeutics with its industry-leading drug delivery technologies, including inhaleable powdered drugs for treating systemic and local lung indications.

"As a leader in advanced inhaleable powdered drug products, Nektar has an understanding of the value and potential of Aerogen's advanced inhaleable liquid capabilities. Aerogen technology and expertise will facilitate the development of certain product opportunities that best lend themselves to an inhaleable liquid delivery system," John C. Hodgman, Aerogen president and chief executive officer said in the release.

The transaction will have both cash and stock components, with Nektar providing approximately $8 million in cash and approximately $24 million in stock with the option of paying all in cash as described below.
Under the terms of the agreement each share of common stock will be exchanged for a total of approximately $0.75 per common share, comprising either $0.1875 in cash, and approximately $0.5625 per common share in Nektar common stock (valued based on the volume-weighted average price of Nektar common stock during the twenty trading days ended two days prior to the completion of the acquisition) or all cash as discussed below. Also upon completion of the acquisition, each share of Aerogen A-1 preferred stock will be exchanged for a total of approximately $29.0251 per A-1 Preferred share, comprising either $7.2563 in cash, and approximately $21.7688 in Nektar common stock (valued as described above), or all cash.
At any time prior to September 15, 2005, Nektar may, at its sole discretion, elect to pay the entire consideration in cash, resulting in payments to Aerogen stockholders of approximately $0.75 in cash per common share and approximately $29.0251 in cash per A-1 Preferred share. It is anticipated that the merger will be treated as a taxable transaction. The premium over the average closing price per common share over the last 30 trading days is 50%.

The boards of directors of Nektar and Aerogen have approved the transaction, which is subject to Aerogen shareholders' approval and other customary closing conditions. The transaction is anticipated to be consummated sometime in the fourth quarter of this year. The transaction does not affect Nektar's previous guidance for year-end 2005 cash balance of greater than $270 million.

Aerogen, Inc. has commercialized its Aeroneb Micropump Nebulizer products for hospital, home and pre-clinical use through a network of world-class respiratory distribution partners that includes Puritan-Bennett, Respironics, Maquet, Cardinal Health, Evo Medical Solutions, and Buxco. Aerogen also has development collaborations with pharmaceutical and biotechnology companies for use of its technology in the delivery of novel compounds that treat respiratory and other disorders. Founded in 1990, Aerogen has its headquarters in Mountain View, Calif. with a facility in Galway, Ireland. In 2004, Aerogen reported revenue of $6.2 million and net loss of $10.1 million. For more information, visit www.aerogen.com.
Nektar Therapeutics enables drug delivery technologies, expertise and manufacturing capabilities. The world's top biotechnology and pharmaceutical companies are developing new and better therapeutics using Nektar's advanced technologies and know-how. Nektar also develops its own products by applying its drug delivery technologies and its expertise to existing medicines to enhance performance, such as improving efficacy, safety and compliance. 


Deals and pacts, mergers and acquisitions, lawsuits etc

Second trial on Merck’s painkiller Vioxx begins
17 September, 2005

Impax delisted from Nasdaq

39 drug firms sued over price rigging in California

Chiron rebuffs Novartis' bid

Nasdaq delists Able on bankruptcy filing

Some of the Vioxx suits may be settled: Merck

Glaxo Smithkline in pact with IAVI to develop AIDS drug

Pfizer acquires Vicuron Pharma for $1.9 billion

Ranbaxy acquires generic product portfolio from Efarmes

Novasite Pharma buys PsyCheNomicS

Temasek sets up $112 million pharma JV

Able Laboratories files bankruptcy suit with US court

Cardiac Science-Defibtech lawsuit settled

Par loses ondansetron case to GSK

Florida sues Mylan, Teva and Watson

Lupin in pact with Kyowa of Japan

British Pharma seeks opinion on industry code

European biotech start-ups fail to win late-stage funds

Afghan’s first generics plant to go on stream by Oct. ‘05

Merck sets up generic arm Genpharm in US

Novo Nordisk, Eli Lilly remove insulin products from Australia

Glaxo inks co-promotion pact with Eisai for Paritec

Elder Pharma plans unit, brand acquisition

Nectar Lifesciences plans Rs 90 crore IPO

Genepharm in pact with 3 Australian distributors 

Novartis acquires Bristol-Myers’ OTC business in US

Novartis completes Eon Labs buy

Orbus inks supply pact with Docpharma 

Novartis acquires rights of kidney dialysis drug from SeBo

Nektar buys out Aerogen for $32 m

BioVeris licenses Baxter's vaccine portfolio

Carl Icahn sells Mylan shares

Dey and Connecticut settle pricing dispute

   Pharma Home


Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us